18 withdrawn. 18 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Withdrawn 18 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis Emicizumab, FEIBA, rFVIIa - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2026-09-01 | 2026-11-06 | |
| A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis Coagadex(R) - Acquired Factor X Deficiency | Phase 3 | Withdrawn | Kedrion S.p.A. | 2026-06-01 | 2026-11-05 | |
| Study of a Gene Therapy Treatment for Hemophilia A SPK-8011 - Hemophilia A | Phase 3 | Withdrawn | Spark Therapeutics, Inc. | 2024-03-13 | 2024-12-13 | |
| FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis FIB Grifols - Congenital Afibrinogenemia, Hypofibrinogenemia | Phase 3 | Withdrawn | Instituto Grifols, S.A. | 2023-12-01 | 2023-10-23 | |
| Emicizumab PUPs and Nuwiq ITI Study Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol) - Hemophilia A | Phase 3 | Withdrawn | Emory University | 2022-02-17 | 2024-01-05 | |
| Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months Avatrombopag 20 mg Oral Tablet - Immune Thrombocytopenia | Phase 3 | Withdrawn | Sobi, Inc. | 2021-10-14 | 2021-10-22 | |
| Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform Eloctate Prophylaxis, Emicizumab Prophylaxis, Eloctate ITI plus Emicizumab - Severe Hemophilia A | Phase 3 | Withdrawn | Margaret Ragni | 2020-08-01 | 2019-08-20 | |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) efgartigimod, Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Withdrawn | argenx | 2020-06-29 | 2020-09-14 | |
| Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia Rituximab, Dexamethasone, Mycophenolate mofetil - Immune Thrombocytopenia | Phase 3 | Withdrawn | Weill Medical College of Cornell University | 2016-12-01 | 2018-08-14 | |
| MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP Blisibimod, Placebo - Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Withdrawn | Anthera Pharmaceuticals | 2015-12-01 | 2015-07-30 | |
| A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP） Cyclosporin A, rhTPO - Immune Thrombocytopenia | Phase 3 | Withdrawn | Shandong University | 2014-07-01 | 2016-04-20 | |
| A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP） Rituximab - Immune Thrombocytopenia | Phase 3 | Withdrawn | Shandong University | 2014-05-01 | 2016-04-20 | |
| Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B IB1001 - Hemophilia B | Phase 3 | Withdrawn | Cangene Corporation | 2014-03-01 | 2016-08-23 | |
| All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) All-Trans Retinoid Acid(ATRA), Dexamethasone - Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Withdrawn | Shandong University | 2013-02-01 | 2016-04-20 | |
| Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) recombinant human thrombopoietin (rhTPO); rituximab, Dexamethasone - Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Withdrawn | Shandong University | 2012-07-01 | 2016-04-20 | |
| The Plasma Large-Volume Exchange RCT Plasma Exchange - Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome | Phase 3 | Withdrawn | London Health Sciences Centre | 2012-04-01 | 2013-04-17 | |
| Fibrinogen Concentrate (Human) - Efficacy and Safety Study Fibrinogen Concentrate, Human (FCH), Cryoprecipitate - Afibrinogenemia, Hypofibrinogenemia | Phase 3 | Withdrawn | CSL Behring | 2009-10-01 | 2023-02-06 | |
| Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures FFP Infusion - Blood Coagulation Disorders | Phase 3 | Withdrawn | Massachusetts General Hospital | 2006-03-01 | 2014-06-06 |
Purpura, Thrombocytopenic, Idiopathic (8) · Hemophilia A (5) · Afibrinogenemia (2) · Hematologic Diseases (2) · Hemophilia B (2) · Hemorrhagic Disorders (2) · Purpura (2) · Blood Coagulation Disorders, Inherited (1) · Coagulation Protein Disorders (1) · Factor X Deficiency (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Hemolytic-Uremic Syndrome (1) · Immunoglobulin Light-chain Amyloidosis (1)
Hemic and Lymphatic Diseases (18) · Hematologic Diseases (16) · Hemorrhagic Disorders (14) · Blood Platelet Disorders (9) · Cytopenia (9) · Hemorrhage (9) · Immune System Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Purpura, Thrombocytopenic (9) · Signs and Symptoms (9) · Skin Manifestations (9) · Thrombocytopenia (9) · Thrombotic Microangiopathies (9)
Dexamethasone (3) · Rituximab (3) · emicizumab (3) · Fibrinogen (2) · AMG623 peptibody (1) · Calcium Dobesilate (1) · Clinical Protocols (1) · Cyclosporine (1) · Factor VIII (1) · IB1001 (1) · Mycophenolic Acid (1) · Plasma Exchange (1) · Tablets (1) · Thrombopoietin (1) · Tretinoin (1)
Shandong University (4) · Emory University (2) · Anthera Pharmaceuticals (1) · CSL Behring (1) · Cangene Corporation (1) · Instituto Grifols, S.A. (1) · Kedrion S.p.A. (1) · London Health Sciences Centre (1) · Margaret Ragni (1) · Massachusetts General Hospital (1) · Sobi, Inc. (1) · Spark Therapeutics, Inc. (1) · Weill Medical College of Cornell University (1) · argenx (1)
United States (6) · China (4) · Canada (1) · United Kingdom (1)
Ming Hou, Dr. (3) · Robert Sidonio, MD (2) · Barbara Konkle, MD (1) · Christopher D. Hillyer, MD (1) · Darrell Triulzi, MD (1) · David Kuter, MD (1) · George Buchanan, MD (1) · James B. Bussel, M.D (1) · James Bussel, MD (1) · James R. Stubbs, MD (1) · Janice McFarland, MD (1) · Jeffrey McCullough, MD (1) · John Hess, MD, MPH (1) · Margaret V Ragni, MD, MPH (1) · Mark Brecher, MD (1)
PMID 12944568, PMID 17077333, PMID 18510702, PMID 19005182, PMID 19846889, PMID 31003964
2018 (1), 2023 (1), U01HL072028 (1), U01HL072072 (1), U01HL072191 (1), U01HL072196 (1), U01HL072248 (1), U01HL072283 (1), U01HL072289 (1), U01HL072290 (1), U01HL072291 (1), U01HL072299 (1), U01HL072305 (1), U01HL072331 (1), U01HL072346 (1)